Anne Muir joins the firm as director of portfolio from the University of Dundee, where she was deputy director for research and innovation services and previously head of IP and commercialisation, while Rob Halliday joins as investment director from SIS Ventures, where he was a senior investment manager.

The pair join recent recruits Jill Arnold, the former head of SIS Ventures who is now investment relationship director at Eos, and Calum Keddie, investment executive at Eos, who began his career on Rolls Royce’s commercial graduate programme before taking up a financial analyst role with Dutch bank ING.

Andrew McNeill, Eos’s managing partner, said: “The growth of the portfolio and the overall quantum of our investments means we needed to build more capacity and expertise. We couldn’t be happier to have Anne and Rob join Jill and Calum on the executive team. Together with our advisory team, we now have the right mix to guide us and our portfolio companies through the next phase of growth.”

Eos has also completed the third annual close of the Eos Innovation Fund (EIS), which is the cornerstone of the firm’s investment model, enabling Eos to invest £15-20 million per annum at the seed stage.

Eos, which invests into predominantly Scottish science and technology companies that are addressing key global issues, recently returned a double-digit return to investors from portfolio company ENOUGH (previously 3F Bio), the first of two exits during Q4.

Mark Beaumont, partner at Eos, said: “The Eos Innovation Fund has allowed us to work with individual investors, companies, and family offices in a way we couldn’t when we only operated as an angel group.

“The concept of an annual subscription gives us far greater certainty in access to capital and allows our investors to have a long term stake in a portfolio of highly impactful and high potential companies, all focused on areas of sustainability and quality of life.”

Eos’s portfolio includes Bioliberty, Carcinotech, Chromacity, Cumulus Oncology, Dxcover, Nth, Green Bioactives, GM Flow, ILC Therapeutics, Laverock Therapeutics, Naturbeads, Novosound, Penrhos Bio, RAB Microfluidics, Rooser, Waire Health, Wobble Genomics, and Chemify.